89. リンパ脈管筋腫症
[臨床試験数:38,薬物数:42(DrugBank:19),標的遺伝子数:26,標的パスウェイ数:134

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03253913
(ClinicalTrials.gov)
March 31, 201810/8/2017Resveratrol and Sirolimus in Lymphangioleiomyomatosis TrialResveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)LymphangioleiomyomatosisDrug: Sirolimus;Drug: ResveratrolUniversity of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Unknown status18 YearsN/AFemale25Phase 2United States
2NCT03150914
(ClinicalTrials.gov)
January 1, 201810/5/2017Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialMulticenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialLAM;LymphangioleiomyomatosisDrug: SirolimusUniversity of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS);The LAM FoundationRecruiting18 YearsN/AFemale60Phase 3United States
3NCT02432560
(ClinicalTrials.gov)
March 20154/3/2015Safety and Durability of Sirolimus for Treatment of LAMMulticenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)LymphangioleiomyomatosisDrug: Sirolimus;Drug: EverolimusUniversity of CincinnatiRare Diseases Clinical Research Network;National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);The LAM FoundationActive, not recruiting18 YearsN/AFemale600United States
4JPRN-UMIN000016677
2015/01/0102/03/2015Efficacy and safety of low dose sirolimus in lymphangioleiomyomatosis lymphangioleiomyomatosissirolimus 1mg/day / sirolimus 2mg/dayNational Hospital Organization Kinki-chuo Chest Medical CenterNULLRecruitingNot applicableNot applicableMale and Female20Not selectedJapan
5NCT02061397
(ClinicalTrials.gov)
March 201423/1/2014Safety of Simvastatin in LAM and TSCThe Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)Lymphangioleiomyomatosis;Tuberous Sclerosis ComplexDrug: Simvastatin;Drug: Sirolimus Oral Product;Drug: Everolimus Oral ProductUniversity of PennsylvaniaThe LAM FoundationCompleted18 YearsN/AFemale10Phase 1/Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-JMA-IIA00096
05/09/201217/08/2012multicenter lymphangioleiomyomatosis sirolimus trial for safetymulticenter lymphangioleiomyomatosis sirolimus trial for safety lymphangioleiomyomatosisIntervention type:DRUG. Intervention1:Srolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years and modified dosage between 1mg and 3mg QD depend on the plasma concentration monitoring..Koh Nakata, MD, PhDYoshikazu InoueKuniaki SeyamaRyushi TazawaToshinori TakadaCompleted>=18 YEARSNo LimitFemale65Phase 2Japan
7NCT01687179
(ClinicalTrials.gov)
September 20122/8/2012Safety Study of Sirolimus and Hydroxychloroquine in Women With LymphangioleiomyomatosisTargeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and SirolimusLymphangioleiomyomatosisDrug: Sirolimus and Hydroxychloroquine 200 mg;Drug: Sirolimus and Hydroxychloroquine 400 mgBrigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Completed18 Years85 YearsFemale14Phase 1United States
8JPRN-UMIN000007387
2012/03/3101/04/2012Clinical trials for long-term administration of sirolimus for lymphangioleiomyomatosisClinical trials for long-term administration of sirolimus for lymphangioleiomyomatosis - Long-term administration of sirolimus for lymphangioleiomyomatosis lymphangioleiomyomatosissirolimusKobe University Graduate School of MedicineNULLComplete: follow-up completeNot applicableNot applicableFemale1Not applicableJapan
9JPRN-JMA-IIA00037
01/10/201115/03/2010MLLTS trialMulticenter Lymphangioleiomyomatosis Long Term Sirolimus Trial lymphangioleiomyomatosisIntervention type:DRUG. Intervention1:sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years..Koh Nakata, MD, Ph.DRyushi TazawaOther>=18 YEARSNo LimitFemale50Phase 2Japan
10JPRN-JMA-IIA00011
08/05/200829/06/2007Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial)Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial) Lymphangioleiomyomatosis (LAM)Intervention type:DRUG. Intervention1:Sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:12 months on, 12 months off. Control intervention1:Placebo, Dose form:TABLET, Route of administration:ORAL, Intended dose regimen:12 months on, 12 months off.Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicinea.Alan F. Barker, M.D. - Oregon Health & Sciences University b.Kevin Brown, M.D., - National Jewish Medical & Research Center c.Edwin K. Silverman, M.D., Ph.D. - Harvard/Brigham & Women's Hospital d.James M. Stocks, M.D. - University of Texas Health Centere.James K. Stoller, M.D. - Cleveland Clinic Foundation f.Charlie Strange, M.D. - Medical University of South Carolina g.Bruce Trapnell, M.D.-Cincinnati Children's Medical Centerh.Mark Brantly, M.D.-University of Florida, Gainesvillei.Yosdhikazu Inoue, M.D., National Hospital Organization (NHO) Kinki-Chuo Chest Medical Centerj.Koh Nakata, M.D., Ph.D., Bioscience Medical Research Center, Niigata University Medical and Dental Hospitalk.Joel Moss, M.D., Ph.D-National Institutes of HealthCompleted>=18 YEARSFemale120Phase 3Japan, United States, Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00414648
(ClinicalTrials.gov)
December 200620/12/2006Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)Lymphangioleiomyomatosis Efficacy and Safety TrialLymphangioleiomyomatosisDrug: Sirolimus;Drug: Placebo sirolimusOffice of Rare Diseases (ORD)FDA Office of Orphan Products DevelopmentActive, not recruiting18 YearsN/AFemale120Phase 3United States;Canada;Japan
12NCT00490789
(ClinicalTrials.gov)
October 200521/6/2007Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMA Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;LymphangioleiomyomatosisDrug: sirolimusCardiff UniversityUniversity of Nottingham;St Georges Hospital Medical School;Royal Sussex County Hospital;The Tuberous Sclerosis Association;Wyeth is now a wholly owned subsidiary of PfizerActive, not recruiting18 Years65 YearsBoth14Phase 2United Kingdom
13NCT00457808
(ClinicalTrials.gov)
December 20026/4/2007Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMRapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;LymphangioleiomyomatosisDrug: Rapamycin, sirolimusChildren's Hospital Medical Center, CincinnatiThe LAM Foundation;Tuberous Sclerosis AllianceCompleted18 Years65 YearsBoth25Phase 2United States